JP2009534397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534397A5 JP2009534397A5 JP2009506662A JP2009506662A JP2009534397A5 JP 2009534397 A5 JP2009534397 A5 JP 2009534397A5 JP 2009506662 A JP2009506662 A JP 2009506662A JP 2009506662 A JP2009506662 A JP 2009506662A JP 2009534397 A5 JP2009534397 A5 JP 2009534397A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pyrimidinediamine
- fluoro
- neoplasm
- oxazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 23
- -1 2-Methyl-1H-benzo [d] imidazol-6-ylamino Chemical group 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229940043355 kinase inhibitor Drugs 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 241000700605 Viruses Species 0.000 claims 6
- 102000006495 integrins Human genes 0.000 claims 4
- 108010044426 integrins Proteins 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 206010061187 Haematopoietic neoplasm Diseases 0.000 claims 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 102000000551 Syk Kinase Human genes 0.000 claims 3
- 108010016672 Syk Kinase Proteins 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000012526 B-cell neoplasm Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000025317 T-cell and NK-cell neoplasm Diseases 0.000 claims 2
- 201000006491 bone marrow cancer Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- WQORWQOZXXZELT-UHFFFAOYSA-N 5-fluoro-2-n-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(N)C(F)=CN=2)=C1 WQORWQOZXXZELT-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 1
- 102000008607 Integrin beta3 Human genes 0.000 claims 1
- 108010020950 Integrin beta3 Proteins 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical group N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 238000011789 NOD SCID mouse Methods 0.000 description 6
- 238000011887 Necropsy Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102100035634 B-cell linker protein Human genes 0.000 description 4
- 101710083670 B-cell linker protein Proteins 0.000 description 4
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 229960002411 imatinib Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 102000056982 human CD33 Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/407,233 | 2006-04-18 | ||
| US11/407,233 US8227455B2 (en) | 2005-04-18 | 2006-04-18 | Methods of treating cell proliferative disorders |
| PCT/US2007/064511 WO2007124221A1 (en) | 2006-04-18 | 2007-03-21 | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009534397A JP2009534397A (ja) | 2009-09-24 |
| JP2009534397A5 true JP2009534397A5 (enExample) | 2011-05-12 |
| JP5204761B2 JP5204761B2 (ja) | 2013-06-05 |
Family
ID=38477280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506662A Active JP5204761B2 (ja) | 2006-04-18 | 2007-03-21 | ピリミジンジアミン化合物を使用することによる細胞増殖性障害を処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8227455B2 (enExample) |
| EP (1) | EP2010181B1 (enExample) |
| JP (1) | JP5204761B2 (enExample) |
| AT (1) | ATE499102T1 (enExample) |
| CA (1) | CA2649549C (enExample) |
| DE (1) | DE602007012677D1 (enExample) |
| DK (1) | DK2010181T3 (enExample) |
| ES (1) | ES2364657T3 (enExample) |
| SI (1) | SI2010181T1 (enExample) |
| WO (1) | WO2007124221A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1663242T3 (da) * | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| US20090048214A1 (en) * | 2006-11-15 | 2009-02-19 | Rigel Pharmaceuticals, Inc | Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds |
| WO2009003136A1 (en) * | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| US20090088371A1 (en) * | 2007-08-28 | 2009-04-02 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
| PT2217241T (pt) * | 2007-11-07 | 2018-06-11 | Rigel Pharmaceuticals Inc | Granulação por via húmida utilizando um agente sequestrante de água |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| MX2011000117A (es) | 2008-07-10 | 2011-02-25 | Toray Industries | Composicion farmaceutica para tratamiento y prevencion de cancer. |
| CN102292333B (zh) | 2009-01-15 | 2015-05-13 | 里格尔药品股份有限公司 | 蛋白激酶c抑制剂及其用途 |
| EP2501705B1 (en) | 2009-11-20 | 2014-08-27 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| US8618095B2 (en) | 2010-04-13 | 2013-12-31 | Rigel Pharmaceuticals, Inc. | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| WO2011144742A1 (en) | 2010-05-21 | 2011-11-24 | Chemilia Ab | Novel pyrimidine derivatives |
| PH12012502572A1 (en) | 2010-06-30 | 2022-03-30 | Fujifilm Corp | Novel nicotinamide derivative or salt thereof |
| EP2688883B1 (en) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidine derivatives |
| WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
| EP2736487B2 (en) | 2011-07-28 | 2024-08-28 | Rigel Pharmaceuticals, Inc. | New (trimethoxyphenylamino)pyrimidinyl formulations |
| JP5868168B2 (ja) | 2011-12-28 | 2016-02-24 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| UY34807A (es) | 2012-05-16 | 2013-12-31 | Novartis Ag | Derivados monocíclicos de heteroarilcicloalquil- diamina |
| WO2013189241A1 (zh) * | 2012-06-20 | 2013-12-27 | 上海恒瑞医药有限公司 | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 |
| CN103804382A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
| CN103102412B (zh) * | 2013-01-29 | 2014-03-26 | 陈仁杰 | 人源抗鼻咽癌LMP2A胞外区抗体Fab及其应用 |
| MX2017009595A (es) * | 2015-01-23 | 2018-04-20 | Univ Erasmus Med Ct Rotterdam | Compuestos antisenescentes y usos de los mismos. |
| ES2913119T3 (es) * | 2015-08-12 | 2022-05-31 | Portola Pharm Inc | Cerdulatinib para tratar mieloma |
| EA038890B1 (ru) | 2015-11-02 | 2021-11-03 | Блюпринт Медсинс Корпорейшн | Ингибиторы ret |
| RU2621187C1 (ru) * | 2016-05-13 | 2017-06-01 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
| US10111882B2 (en) | 2016-09-14 | 2018-10-30 | Gilead Sciences, Inc. | SYK inhibitors |
| WO2018195471A1 (en) | 2017-04-21 | 2018-10-25 | Gilead Sciences, Inc. | Syk inhibitors in combination with hypomethylating agents |
| CA3096043A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| KR20230017234A (ko) | 2020-05-29 | 2023-02-03 | 블루프린트 메디신즈 코포레이션 | 프랄세티닙의 고체 형태 |
| WO2023182460A1 (ja) * | 2022-03-24 | 2023-09-28 | 学校法人 聖マリアンナ医科大学 | 慢性活動性Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス感染症（ＣＡＥＢＶ）の検出方法 |
| WO2024037910A1 (en) * | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Syk inhibitors for use in the treatment of cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| ATE261730T1 (de) * | 1997-12-31 | 2004-04-15 | Univ Kansas | Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| EP1343782B1 (en) | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003026666A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
| WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
| AU2002367172A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| NZ535365A (en) * | 2002-03-20 | 2006-07-28 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
| CN103169708B (zh) | 2002-07-29 | 2018-02-02 | 里格尔药品股份有限公司 | 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
| WO2004014832A2 (en) | 2002-08-02 | 2004-02-19 | Vanetta S.P.A. | Redox process particularly for the production of menadione and use of polyoxometalates |
| WO2004087698A2 (en) | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| DK1663242T3 (da) | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
| WO2005027848A2 (en) | 2003-09-19 | 2005-03-31 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators |
| US20050165031A1 (en) * | 2003-11-13 | 2005-07-28 | Ambit Biosciences Corporation | Urea derivatives as ABL modulators |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| US20090048214A1 (en) | 2006-11-15 | 2009-02-19 | Rigel Pharmaceuticals, Inc | Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds |
-
2006
- 2006-04-18 US US11/407,233 patent/US8227455B2/en active Active
-
2007
- 2007-03-21 AT AT07759007T patent/ATE499102T1/de not_active IP Right Cessation
- 2007-03-21 EP EP07759007A patent/EP2010181B1/en active Active
- 2007-03-21 WO PCT/US2007/064511 patent/WO2007124221A1/en not_active Ceased
- 2007-03-21 JP JP2009506662A patent/JP5204761B2/ja active Active
- 2007-03-21 ES ES07759007T patent/ES2364657T3/es active Active
- 2007-03-21 CA CA2649549A patent/CA2649549C/en active Active
- 2007-03-21 SI SI200730591T patent/SI2010181T1/sl unknown
- 2007-03-21 DK DK07759007.3T patent/DK2010181T3/da active
- 2007-03-21 DE DE602007012677T patent/DE602007012677D1/de active Active
-
2012
- 2012-06-04 US US13/487,979 patent/US8481521B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534397A5 (enExample) | ||
| Jiang et al. | Disruption of Wnt/β-catenin exerts antileukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia | |
| AU2011302344B2 (en) | HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients | |
| US11202779B2 (en) | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors | |
| US12083136B2 (en) | Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof | |
| JPWO2016204193A1 (ja) | 抗がん剤 | |
| TW202216208A (zh) | 抗體-藥物結合物及atr抑制劑之組合 | |
| JP2014520808A (ja) | Ｈｓｐ９０阻害化合物を用いた癌の治療 | |
| WO2018152548A4 (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| WO2023140846A1 (en) | Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway | |
| JP6558757B2 (ja) | 抗腫瘍剤 | |
| JP6063472B2 (ja) | 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 | |
| WO2017159877A1 (en) | Use of eribulin and 3-quinuclidinone derivatives in the treatment of cancer | |
| US11491168B2 (en) | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof | |
| Allen et al. | The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer | |
| BR112021015908A2 (pt) | Composição antitumoral | |
| TW202339805A (zh) | 抗體-藥物結合物及atr抑制劑之組合 | |
| Wei et al. | Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer | |
| JP7493503B2 (ja) | Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物 | |
| JP2013523867A5 (enExample) | ||
| JP6886278B2 (ja) | 抗癌剤 | |
| Yi et al. | Recent advances in understanding and managing T-cell lymphoma | |
| JP5802658B2 (ja) | 人および動物の腫瘍性疾患の治療、抑制あるいは予防用医薬組成物、および医薬組成物の使用 | |
| TW201008945A (en) | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents | |
| JP5987175B2 (ja) | 乳癌，胃癌及び卵巣癌等に対する制癌剤 |